secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001558370-25-010507
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028
--------------------------------------------------------------------

- Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
- Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.
- Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.
- Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.
- Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/0001558370-25-010507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837025010507/vygr-20250806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer